🔥Pembrolizumab + chemo for metastatic NSCLC with PD-L1 TPS < 1%
🎙️Dr. Shirish M. Gadgeel JTO & JTO CRR IASLC
🎯KEYNOTE series trials after 5 years of F/U
✅Pooled Analysis
✅Primary: OS
✅NCT02578680, NCT03950674, NCT02775435, NCT03875092
#LCSM OncoAlert
jto.org/article/S1556-…

sites.libsyn.com/427415/liquid-…
With Christian Rolfo Icahn School of Medicine at Mount Sinai #lungcancer #liquidbiopsy

🚨Thanks ⁦⁦Dr Rafeq Naqash Rafeh Naqash, MD⁩ for the kind invitation to ⁦JCO Precision Oncology⁩ conversations podcast 🎤on our paper📝“Liquid Biopsy of Lung Cancer Before Path Diagnosis”⁦⁩ ⁦Alessandro Russo⁩ ⁦Lincoln Pasquina⁩ ⁦ASCO⁩ sites.libsyn.com/427415/liquid-…

International Society of Liquid Biopsy
The Tisch Cancer Institute
ASCO JCO Precision Oncology

Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation aacrjournals.org/clincancerres/…

The U.S. FDA has granted breakthrough therapy designation to sunvozertinib (DZD9008) from Dizal Pharmaceutical as frontline treatment for patients with metastatic NSCLC whose disease harbors an EGFR exon 20 insertion mutation! more options for our EGFR Resisters patients EGFR Resisters Research Summit…

Moving Forward Liquid Biopsy in Early Liver Cancer Detection aacrjournals.org/cancerdiscover…
Christian Rolfo Alessandro Russo #liquidbiopsy #livercancer

And our editorial to this great paper ! Alessandro Russo

Cancer Discovery Elizabeth McKenna

International Society of Liquid Biopsy

aacrjournals.org/cancerdiscover…

Glad to share our paper just published in Cancer Discovery that characterizes mutations in the MET kinase domain in lung cancer and other malignancies from a clinical, preclinical and structural point of view.
doi.org/10.1158/2159-8…

Membrane targets for novel therapeutics in RET+ NSCLC
Check our work at #AACR24 Section 44 (7)
#RET MAP Arianna Marinello, MD Gustave Roussy

New Treatment Options for Patients With Oncogene-Addicted Non–Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors | American Society of Clinical Oncology Educational Book ascopubs.org/doi/10.1200/ED… #ASCO24

Time is Running Out! You are invited to participate in the #WCLC24 by submitting your scientific abstract(s). Deadline is April 5, 2024 @ midnight. Guidelines, abstract types accepted, important dates, FAQs & more information available here: wclc2024.iaslc.org/call-for-abstr… #LCSM #IASLC50

A very relevant question for 🩸liquid biopsy: Christian Rolfo et al. Icahn School of Medicine at Mount Sinai
🧬When can we trust a negative result from a ctDNA test and omit tissue biopsy?
🧬LB with ctDNA tumor fraction ≥1% accurately identifies true negative results in lung cancer, reducing the need…

Most viewed in the last 7 days from JAMA Oncology:

Do patients with resectable NSCLC and tumor programmed cell death 1 ligand 1 levels less than 1% benefit from neoadjuvant chemoimmunotherapy?

ja.ma/3TELLl3

Clinical Cancer Research Excited to share this new research in collaboration with Christian Rolfo et al. For more details on this research, click here: bit.ly/43IMS7V

Clinical Cancer Research #Research sought to evaluate a method of distinguishing between scenarios of negative & false-negative liquid biopsy results, as liquid biopsy for tumor profiling is increasingly used to support treatment planning for cancer patients. Highlights here 🔗: bit.ly/43IMS7V

#NewStudy in Clinical Cancer Research evaluates circulating tumor DNA tumor fraction, a determination of ctDNA in liquid biopsy samples from Foundation Medicine’s blood-based comprehensive genomic profiling test, for its utility in identifying true negative results: bit.ly/43IMS7V

Proud of Diego de Miguel Perez presenting our work EV and COVID19 at Seronet NIH National Cancer Institute A pilot study from a prospective trial Tocilizumab in severe COVID. Using dynamics of EVs, viral prot & other analysis we found important correlations. Stay tuned for the paper The Tisch Cancer Institute

The Program Committee invites you to participate in the #WCLC24 by submitting your scientific abstract(s). Deadline is April 5, 2024 @ midnight. Guidelines, abstract types accepted, important dates, FAQs & more information available here: wclc2024.iaslc.org/call-for-abstr… #LCSM #IASLC50

Shows utility of ctDNA to distinguish negative liquid biopsy results that may benefit from follow-up tissue testing. It supports clinicians to act on negative LB results & begin non-targeted therapy or prioritize obtaining tissue for confirmatory comprehensive genomic profiling.